Cancer Therapies Pipeline | Takeda Oncology
Our Pipeline
Our Pipeline
Our research and development efforts focus on advancing medicines for thoracic, gastrointestinal and hematologic cancers by leveraging modalities best suited to make a difference in the treatment of these diseases. Our core modalities include antibody drug conjugates (ADCs), complex biologics, small molecules and gamma delta T cell therapies.
These therapies in development are investigational and have not been approved by any regulatory bodies for use in the investigational indications listed below.
| Investigational therapy | Modality | Investigational indication | Phase | ||
Brentuximab vedotin* | |||||
ADC | Newly diagnosed Hodgkin lymphoma (EU) | Phase 3 | |||
Cabozantinib* | |||||
Small molecule | Metastatic castration-resistant prostate cancer (JP) | Phase 3 | |||
Dazostinag (TAK-676) | |||||
Small molecule | Solid tumors | Phase 1/2 | |||
Mirvetuximab soravtansine-gynx (TAK-853) | |||||
ADC | Folate receptor alpha (FRα)-positive ovarian cancer (JP) | Phase 1/2 | |||
TAK-012 | |||||
Gamma delta T cell therapy | Acute myeloid leukemia | Phase 1/2a | |||
TAK-186 | |||||
Complex Biologic | Solid tumors | Phase 1/2 | |||
TAK-280 | |||||
Complex Biologic | Solid tumors | Phase 1/2 | |||
TAK-500 | |||||
ADC | Solid tumors | Phase 1/2 |
*Marketed products have received approval in one or more jurisdictions.
All programs have global development rights unless otherwise noted.
GL = global (USA, Europe, Japan, China) / EU = Europe / JP = Japan / CN = China / GEM = global emerging markets
Investors
To learn more about Oncology-specific Investor events and information, visit the Takeda Oncology Investor Relations page
